Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-28

Study Completion Date

2014-02-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a Phase 2, open-label study of KW2871 (ecromeximab) in combination with high-dose interferon-α2b (HDI) in patients with metastatic melanoma. The primary objectives of this study were to assess progression-free survival (PFS) and safety. The secondary objectives were to assess the objective response rate, KW2871 pharmacokinetics (PK), and other exploratory immunology as indicated (e.g., development of human anti-chimeric antibodies \[HACA\], activity of antibody-dependent cell-mediated cytotoxicity \[ADCC\] and complement-dependent cytotoxicity \[CDC\] in peripheral blood, number and functional state of tumor-infiltrating immune cells and expression of GD3 in immune and tumor cells of tumor biopsies, and markers of interferon \[IFN\] response/resistance and markers of resistance to ADCC/CDC in peripheral blood mononuclear cells \[PBMCs\]).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma

NCT00199342

Stage IV Melanoma

TERMINATED PHASE1/PHASE2

Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

NCT00658892

Melanoma (Skin)

COMPLETED PHASE1

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

NCT02129075

Cutaneous Melanoma Melanoma Melanoma of Unknown Primary +9 more

COMPLETED PHASE2

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

NCT00861406

Melanoma

COMPLETED PHASE1

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

NCT00775502

Multiple Myeloma

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients were sequentially enrolled into dose-escalating cohorts to receive KW2871 intravenously (IV) once every 2 weeks starting on Day 3 of Week 1 at the following doses: 5 mg/m\^2 in Cohort 1, 10 mg/m\^2 in Cohort 2, and 20 mg/m\^2 in Cohort 3. HDI was administered concurrently at a dose of 20 million units (MU)/m\^2 IV once daily (QD) for 5 consecutive days per week for 4 weeks (induction phase), followed by 10 MU/m\^2 administered subcutaneously (SC) 3 times per week (maintenance phase). Patients received KW2871 and HDI combination therapy until disease progression requiring treatment intervention that would have interfered with the interpretation of the study results.

Initially, 3 patients were enrolled within a cohort and evaluated for dose-limiting toxicity (DLT) and regimen-limiting toxicity (RLT) for the first 8 weeks of study treatment. If 1 of 3 patients experienced an RLT, the cohort was expanded to 6 patients. Escalation to the next higher dose cohort proceeded if the RLT rate was \<33% (0/3 or 1/6 patients) in a given cohort. The combination treatment was considered safe if ≤ 20% patients experienced RLT.

DLT was defined as any adverse event (AE) that required reduction of the HDI dose or discontinuation of KW2871. RLT was defined as an HDI-related DLT that required more than 2 dose reductions of HDI during the induction phase or the first 4 weeks of the maintenance phase, or any KW2871- or regimen-related DLT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Melanoma Cutaneous Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Dose-escalation cohorts

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

KW2871: 5 mg/m\^2 IV every 2 weeks until disease progression

HDI: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression

Group Type EXPERIMENTAL

HDI

Intervention Type DRUG

20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression

KW2871

Intervention Type DRUG

5 mg/m\^2 IV every 2 weeks until disease progression

Cohort 2

KW2871: 10 mg/m\^2 IV every 2 weeks until disease progression

HDI: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression

Group Type EXPERIMENTAL

HDI

Intervention Type DRUG

20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression

KW2871

Intervention Type DRUG

10 mg/m\^2 IV every 2 weeks until disease progression

Cohort 3

KW2871: 20 mg/m\^2 IV every 2 weeks until disease progression

HDI: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression

Group Type EXPERIMENTAL

HDI

Intervention Type DRUG

20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression

KW2871

Intervention Type DRUG

20 mg/m\^2 IV every 2 weeks until disease progression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HDI

20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression

Intervention Type DRUG

KW2871

5 mg/m\^2 IV every 2 weeks until disease progression

Intervention Type DRUG

KW2871

10 mg/m\^2 IV every 2 weeks until disease progression

Intervention Type DRUG

KW2871

20 mg/m\^2 IV every 2 weeks until disease progression

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Interferon-α2b Intron A Ecromeximab Ecromeximab Ecromeximab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years of age.
2. Histologically proven metastatic cutaneous, mucosal, or unknown primary melanoma.
3. Measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST).
4. Ambulatory (Eastern Cooperative Oncology Group \[ECOG\] performance status 0 or 1) or expected survival ≥ 4 months.
5. Within the last 2 weeks prior to study day 1, the following laboratory parameters within the ranges specified:

* Hemoglobin: ≥ 9 g/dL
* Platelets: ≥ 100 x 10\^9/L
* Neutrophils: ≥ 1.5 x 10\^9/L
* International normalized ratio: ≤ 2.0 (≤ 3.0 if on warfarin therapy)
* Serum creatinine: ≤ 1.5 x upper limit of normal (ULN)
* Serum total bilirubin: ≤ 1.5 x ULN
* Aspartate aminotransferase/alanine aminotransferase: ≤ 2.5 x ULN
6. Able and willing to give valid written informed consent.

Exclusion Criteria

1. Other malignancy within 3 years prior to study entry for which the patient received active treatment, except for treated melanoma or non-melanoma skin cancer, cervical cancer, and breast carcinoma in situ.
2. Mental impairment that may have compromised the ability to give informed consent and comply with the study requirements.
3. Participation in any other clinical trial involving chemotherapy, radiotherapy, or other immunotherapy within 4 weeks prior to study enrollment.
4. Prior exposure to anti-GD3 antibodies.
5. Pregnancy or breastfeeding.
6. Women of childbearing potential who refused or were unable to use effective means of contraception.
7. Active autoimmune or other disorders that required systemic treatment with immunomodulatory or immunosuppressant medications (i.e., corticosteroids, cyclophosphamide, methotrexate, other biologics). Corticosteroids at substitution doses were allowed.
8. Metastatic brain disease was allowed provided that appropriate treatment had been administered (surgery or irradiation) and 2-month follow-up by brain magnetic resonance imaging (MRI) showed disease control (stability or regression).
9. Autoimmune-related hypothyroidism and vitiligo-like depigmentation were allowed provided the patient was medically stable with treatment (thyroid-hormone replacement or observation).
10. Serious medical illness, such as cardiovascular disease (uncontrolled congestive heart failure or hypertension, active ischemic disease of the heart \[angina\], recent \[\<3 months\] myocardial infarction, severe cardiac arrhythmia), bleeding disorders, obstructive or restrictive pulmonary diseases, active systemic infections requiring antibiotics, serious intercurrent illness requiring hospitalization, inflammatory bowel disorders, or significant psychiatric disease, which in the opinion of the principal investigator would have prevented adequate informed consent or rendered study treatment unsafe or contraindicated.
11. Patients with clinical suspicion of human immunodeficiency virus (HIV) or hepatitis underwent the following viral tests: patients with HIV must have had negative antibodies; patients with hepatitis B virus must have had negative antigens; patients with hepatitis C virus must have had a negative test for serum antibodies. If any of the tests were positive, patients were excluded from the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No